LTGO

Latigo Biotherapeutics Inc

17.15

Sep 25 • 3:59 PM ET -0.61 (-3.43%)

17.15

Aftermarket • 7:30 PM ET 0.00 (0.00%)

Healthcare Biotechnology USA Small NASD

Held by: SCHA VTI VXF SCHB VTWO VTWG VTWV VTHR

Scroll to Statements

Index	-
Market Cap	1.14B
Enterprise Value	1.40B
Income	-
Sales	-
Book/sh	-4.16
Cash/sh	0.83
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	-
IPO	Aug 07, 2026

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	-
P/C	20.60
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	1.15
Current Ratio	1.15
Debt/Eq	2.50
LT Debt/Eq	0.05
Option/Short	No / Yes

EPS (ttm)	-
EPS next Y	-
EPS next Q	-0.62
EPS this Y	-
EPS next Y	-
EPS next 5Y	-
EPS past 3/5Y	- -
Sales past 3/5Y	- -
EPS Y/Y TTM	-
Sales Y/Y TTM	-
EPS Q/Q	-
Sales Q/Q	-
Earnings	Sep 03 AMC
EPS/Sales Surpr.	0.00% -

Insider Own	58.23%
Insider Trans	0.73%
Inst Own	14.69%
Inst Trans	12.81%
ROA	-
ROE	-
ROIC	-
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	-21.69%
SMA50	-19.97%
SMA200	-19.97%
Trades

Shs Outstand	66.30M
Shs Float	27.69M
Short Float	1.62%
Short Ratio	1.19
Short Interest	0.45M
52W High	25.93 -33.86%
52W Low	17.22 -0.41%
Volatility	9.15% 8.92%
ATR (14)	1.84
RSI (14)	33.38
Beta	-
Rel Volume	0.73
Avg Volume	377.77K
Volume	275,688

Perf Week	-23.95%
Perf Month	-28.93%
Perf Quarter	-
Perf Half Y	-
Perf YTD	-18.33%
Perf Year	-
Perf 3Y	-
Perf 5Y	-
Perf 10Y	-
Recom	1.00
Target Price	52.25
Prev Close	17.76
Price	17.15
Change %	-3.43%

Date	Action	Analyst	Rating Change	Price Target Change
Sep-01-26	Initiated	Leerink Partners	Outperform	$36
Sep-01-26	Initiated	Jefferies	Buy	$50
Sep-01-26	Initiated	Guggenheim	Buy	$50
Sep-01-26	Initiated	Goldman	Buy	$73

Sep-03-26 04:05PM

Latigo Biotherapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights

(GlobeNewswire)

Latigo Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company committed to developing innovative non-opioid pain medicines designed to rapidly and effectively stop the transmission of pain without the risk of addiction. Its products include Molecule: LTG-001, Molecule: LTG-32, Molecule: LTG-001 IV and Molecule: LTG-418. The company was founded by Bryan Moyer on November 20, 2018 and is headquartered in Thousand Oaks, CA.

CEOMr. Nima Farzan M.B.A.

Chief Business Officer & CFOMs. Neha Krishnamohan

Chief Medical OfficerDr. Neil Kumar Singla M.D.

Senior Vice President of OperationsMs. Julia Chapman

Vice President of Corporate DevelopmentMs. Caroline Dougherty

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Foresite Capital Management V,	10% Owner	Aug 10 '26	Buy	18.00	140,000	2,520,000	2,008,024	Aug 10 08:21 PM
Tananbaum James B.	Director	Aug 10 '26	Buy	18.00	140,000	2,520,000	2,008,024	Aug 10 08:00 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

LTGO

Latigo Biotherapeutics Inc

Upgrade your Finviz experience